Bioventus Q2 revenue dips 2.4%, organic growth 6.2%

Bioventus

06/08/2025 12:15

Overview

Bioventus Q2 revenue dips 2.4%, organic revenue grows 6.2%

Adjusted EPS rises 31% to $0.21, beating analyst expectations

Co reiterates full-year 2025 guidance for revenue, Adjusted EBITDA, and Non-GAAP EPS

Outlook

Bioventus reiterates 2025 net sales guidance of $560 mln to $570 mln

Company expects 2025 adjusted EBITDA of $112 mln to $116 mln

Bioventus anticipates 2025 non-GAAP EPS of $0.64 to $0.68

Company sees tariff impact as immaterial for 2025 guidance

Result Drivers

DIVESTITURE IMPACT - Revenue decline due to divestiture of Advanced Rehabilitation Business

ORGANIC GROWTH - Organic revenue rose 6.2% driven by double-digit growth in Surgical Solutions and Restorative Therapies

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$147.70 mln
$145.90 mln (4 Analysts)
Q2 Adjusted EPS
Beat
$0.21
$0.2 (3 Analysts)
Q2 Adjusted EBITDA
$33.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Bioventus Inc is $15.00, about 59.1% above its August 5 closing price of $6.14

The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release: ID:nGNX9L37NR

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)